(NASDAQ:BBLG) BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (âBone Biologicsâ or the âCompanyâ) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologicsâ development of NB1 and to review our expected milestones for the coming year, including the anticipated com